Treats acute lymphoblastic leukemia (ALL). ANDA 207812, held by Zydus Pharmaceuticals (USA). Methotrexate Sodium.
As of Nov 21, 2026, ANDA 207812 (Methotrexate Sodium), held by Zydus Pharmaceuticals (USA), was first approved by FDA on Jan 13, 2017, with 3 approved supplements and 0 published complete response letters.
Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 13, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 2.5MG BASE · tablet;oral | Methotrexate Sodium | Rx |
| May 27, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 8, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 8, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 13, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters